Preliminary Validation of a High Content Chemosensitivity Assay

  • Research type

    Research Study

  • Full title

    Preliminary Validation of a High Content Chemosensitivity Assay against paediatric tumours.

  • IRAS ID

    207132

  • Contact name

    Roderick S.P. Benson

  • Contact email

    Rod.Benson@imagentherapeutics.com

  • Sponsor organisation

    Imagen Therapeutics

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    This is a prospective pilot study in which children with a range of tumour types (acute lymphoblastic leukaemia, neuroblastoma, high grade glioma, osteosarcoma), which will be treated with chemotherapy, will be asked to donate tissue and blood samples for research, at the time of their diagnostic biopsy. The samples will be used to grow tumour cells in the laboratory by Imagen Therapeutics. These tumour cells will be tested against a panel of anti-cancer drugs, in a High Content Assay, and a drug-response profile for each patient’s tumour cells will be created.

    The primary aim of the study is to demonstrate that viable tumour material can be collected from patients, at the time of their diagnostic biopsy, and transported to the laboratory in a condition that allows tumour cells to be grown, and that these cells can then be used to generate a drug-response profile in the High Content Assay. The tumour types selected are those in which an early assessment of patient response to treatment is already made, and the secondary aim of the study is to investigate whether the tumour cell drug-response profile is able to predict the patient response to treatment.

    A further aim of the study will be to collect tumour material after chemotherapy, at the time of surgical resection, and to compare tumour cell drug-response profiles at this point with those at diagnosis. The samples collected will be bar-coded to protect patient confidentiality. The drug-response profile of the tumour cells will only be correlated with patient response after the standard clinical evaluation and will not influence the clinical care of the patients enrolled on the study.

  • REC name

    London - Surrey Borders Research Ethics Committee

  • REC reference

    16/LO/1561

  • Date of REC Opinion

    16 Sep 2016

  • REC opinion

    Further Information Favourable Opinion